China Pharma Holdings (CPHI) Consolidated Net Income (2010 - 2026)
China Pharma Holdings (CPHI) posted Consolidated Net Income of -$1.1 million for Q1 2026, up 6.46% on a QoQ basis from -$1.2 million in Q4 2025, and down 45.52% year-over-year from -$2.1 million in Q1 2025.
China Pharma Holdings (CPHI) Consolidated Net Income (2010 - 2026) Analysis & Trends
China Pharma Holdings' Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- Quarterly Consolidated Net Income fell 45.52% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 million (up 22.36% YoY) and the FY2025 annual result came in at -$2.4 million, up 32.7% from the prior year.
- Consolidated Net Income was -$1.1 million for Q1 2026 at China Pharma Holdings, up from -$1.2 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$475976.0 in Q1 2023 and bottomed at -$1.4 million in Q2 2024.
- A 5-year average of -$948160.5 and a median of -$955892.0 in 2024 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2024 — Consolidated Net Income tumbled 142.51% — and 2025, when it jumped 63.26%.
- China Pharma Holdings' Consolidated Net Income stood at -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then gained by 0.63% to -$1.2 million in 2024, then rose by 0.19% to -$1.2 million in 2025, then climbed by 6.46% to -$1.1 million in 2026.
- Business Quant data shows CPHI's Consolidated Net Income at -$1.1 million in Q1 2026, -$1.2 million in Q4 2025, and -$651482.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -651,482.00 |
| Jun 30, 2025 | -528,367.00 |
| Mar 31, 2025 | -785,572.00 |
| Dec 31, 2024 | -1.22 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Jun 30, 2024 | -1.44 Mn |
| Mar 31, 2024 | -955,892.00 |
| Dec 31, 2023 | -1.23 Mn |
| Sep 30, 2023 | -777,600.00 |
| Jun 30, 2023 | -593,029.00 |
| Mar 31, 2023 | -475,976.00 |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | -790,773.00 |
| Jun 30, 2022 | -888,394.00 |
| Mar 31, 2022 | -1.03 Mn |
| Dec 31, 2021 | -980,719.00 |
| Sep 30, 2021 | -826,669.00 |
| Jun 30, 2021 | -824,761.00 |